Edwards Lifesciences’ transcatheter aortic valve replacement (TAVR) system has demonstrated positive results in a long-term trial readout, as global demand for the technology increases. The company ...

SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data ...

Six-year follow-up from a trial comparing surgery with TAVR in low-risk patients showed no difference in major events, but ...

Edwards Lifesciences Corp.’s Sapien 3 platform has been approved for a new indication. The Food and Drug Administration recently cleared the line of catheter-based heart valves, which includes Sapien ...

Edwards Lifesciences had a monumental Q4 and full year 2025, growing sales 13.3% to $1.57 billion in the last quarter of the year. The company’s TAVR and TMTT performance are largely being credited ...

Add Yahoo as a preferred source to see more of our stories on Google. Edwards Lifesciences' Sapien 3 Ultra system. The artificial heart valve is pushed through the blood vessels via a catheter and ...

A Japanese center found that hemolysis was significantly more common after TAVR with the Sapien 3 Ultra Resilia than with its predecessor device, despite the improvement on paravalvular leaks. Annular ...

FDA approved the Sapien 3 transcatheter aortic valve replacement (TAVR) platform for treatment of severe aortic stenosis early in the disease process while patients still had no symptoms or other ...

Edwards Lifesciences Corp. today announced that it received Food and Drug Administration approval for its Sapien 3 platform in asymptomatic patients with severe aortic stenosis. It marks the first ...

The approvals keep rolling in for Edwards Lifesciences. The Irvine, CA-based company said it has won a nod from FDA to approve the Sapien 3 platform, a transcatheter aortic valve replacement therapy ...

SAPIEN 3, which showed superiority at 1 year, also demonstrates compelling outcomes equivalent to surgery at seven years SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (EW) today announced ...